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Rationale: Mixed connective tissue disease is a systemic inflammatory disorder that results in
both pulmonary and esophageal manifestations.
Objectives: We sought to evaluate the relationship between esophageal dysfunction and inter-
stitial lung disease in patients with mixed connective tissue disease.
Methods: We correlated the pulmonary function data and the high-resolution computed
tomography findings of interstitial lung disease with the results of esophageal evaluation in
manometry, 24-hour intraesophageal pH measurements, and the presence of esophageal dila-
tation on computed tomography scan.
Measurements and main results: Fifty consecutive patients with mixed connective tissue
disease, according to Kasukawa’s classification criteria, were included in this prospective
study. High-resolution computed tomography parenchymal abnormalities were present in 39
of 50 patients. Esophageal dilatation, gastroesophageal reflux, and esophageal motor impair-
ment were also very prevalent (28 of 50, 18 of 36, and 30 of 36, respectively). The presence of
interstitial lung disease on computed tomography was significantly higher among patients with
esophageal dilatation (92% vs. 45%; p< 0.01) and among patients with severe motor dysfunc-
tion (90% vs. 35%; p< 0.001).e most common pulmonary abnormalities and the relationship between esophageal dysfunction and
th mixed connective tissue disease.
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Mixed Connective Tissue Disease 855Conclusions: Although we were not able to prove a causal relationship between esophageal
and pulmonary involvement, our series revealed a strong association between esophageal
motor dysfunction and interstitial lung disease in patients with mixed connective tissue
disease.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Mixed connective tissue disease (MCTD) is a systemic
inflammatory disorder in which patients have combinations
of the clinical features of systemic lupus erythematosus,
systemic sclerosis, and polymyositis. Patients with MCTD
typically have high serum titers of antibody to extractable
nuclear antigen (anti-RNP), a feature that has become the
hallmark of the syndrome.1 Although not recognized when
the syndrome was originally described by Sharp and col-
leagues,1e9 pulmonary involvement, mainly interstitial lung
disease, is a major feature of MCTD.
The pathologic mechanisms that trigger interstitial lung
disease in MCTD remain unknown. More recently, gastro-
esophageal reflux and repeated microaspirations have been
associated with interstitial lung disease in patients with
systemic sclerosis.10e14 In patients with idiopathic pulmo-
nary fibrosis, abnormal acid gastroesophageal reflux is very
common, often clinically occult. However, it is not yet
possible to establish gastroesophageal reflux as a risk factor
for idiopathic pulmonary fibrosis.13,15e18 Because pulmo-
nary and esophageal involvements are both common in
MCTD, a link between interstitial lung disease and esoph-
ageal abnormalities should be investigated.19e21 A previous
study21 has shown an association between abnormalities in
pulmonary function tests and esophageal dysfunction in the
radionucleotide scintigraphy (which showed a significant
delay in the clearance of the nucleotide in any segment of
the esophagus) in these patients.
The aim of this study was to describe the most common
pulmonary abnormalities in function tests and in high-
resolution computed tomography in MCTD patients and to
try to establish an association between these findings and
esophageal dilatation in the computed tomography scans,
and between the impairment in the esophageal manometry
and esophageal pH monitoring.
Methods
Fifty consecutive patients with Kasukawa’s classification
criteria for the diagnosis of MCTD were included in the
study (requirement for diagnosis: at least one common
symptom, Raynaud’s phenomenon or swollen fingers or
hands; presence of anti-U1 RNP; and one or more findings in
at least two of three categories e SLE like, polyarthritis,
pericarditis/pleuritis, lymphadenopathy, facial erythema
and leucopenia/thrombocytopenia; scleroderma like, scle-
rodactyly, pulmonary fibrosis and esophageal dysmotility;
and polymyositis like, muscle weakness, high creatine
phosphokinase and myopathic electroneuromyography).22
All patients were seen as outpatients at the Rheumatology
Clinic at Clinical Hospital of Sa˜o Paulo (a large tertiary
hospital) between January 2001 and January 2003. Each
subject was invited to participate in the study and gavewritten informed consent. The study was approved by the
Local Research Ethics Committee.
Pulmonary evaluation
Pulmonary function tests
The following pulmonary function test parameters were
assessed: forced vital capacity (FVC) and forced expiratory
volume at 1 second (FEV1) were measured using standard
spirometric techniques. Predicted and percent predicted
values were calculated for FEV1, FVC and FEV1/FVC ratio
using reference values from Knudson et al. (the Knudson
data set).23 Lung volumes, total lung capacity (TLC), and
residual volume (RV) were obtained by the helium equili-
bration method, and were categorized as normal or low
using lower limit of normal values from the reference
equations of Goldman and Becklake.24 The diffusing
capacity of carbon monoxide (DLCO) was obtained by the
single-breath method, and the reference values are those
of Gaensler and Wright.25 Data are expressed as percent-
ages of predicted values.
High-resolution computed tomography of the lungs
The patients underwent both inspiratory and expiratory
computed tomography scans, which were obtained with the
patients in a prone position. Images were acquired from
lung apices to basis with 2.0-mm collimation, 10-mm
interval (inspiration), and 30-mm interval (expiration),
512 512 matrix. Window levels appropriate for assess-
ment of parenchyma (level e 800 HU; window width:
1200 HU) and mediastinum (level 35 HU; window width:
650 HU) were used. A radiologist (J.K.) blinded to clinical
data, results of function tests, and esophageal evaluations
analyzed the computed tomography scans.
The tomographic images were evaluated to disclose
radiographic abnormalities related to interstitial lung
disease (based on the presence or absence of the features
described below) and the presence of esophageal dilatation:
1. Ground glass opacities: areas of increased attenuation
in which the bronchi and vessels remain visible;
2. Interface sign: irregularity of the interfaces between
the peripheral pleura and aerated lung parenchyma,
defined as subpleural micronodules or small lines
perpendicular to the pleura;
3. Linear opacities: septal and nonseptal lines;
4. Bronchiolectasis or traction bronchiectasis: dilatation
of the airways in the peripheral portion of the lungs;
5. Honeycombing: areas of cystic spaces (diame-
ter< 1 cm) with thickened walls;
6. Air trapping: areas of decreased attenuation and
mosaic perfusion on expiratory computed tomography;
Table 1 Clinical characteristics of MCTD patients.
Patients (n) 50
Sex (male/female) 1/49
Median age (years) 43 (23e66)
Median duration
of the disease (years)
8 (1e23)
Smokers or ex-smokers 8/50
Shortness of breath 19/50
Reflux symptoms 37/50
Patients receiving prednisone 38/50
Patients receiving
immunosupressive drugs
9/50
Values in parentheses are ranges.
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with a large collection of intraluminal air (exceeding
10 mm in the coronal plane) on 4 or more consecutive
axial images. The esophagus is also considered dilated
when it is fluid filled or has an air-fluid level.26
Esophageal investigations
Medications that might affect esophageal motility or acid
gastroesophageal reflux (antacids, metoclopramide, cis-
apride, calcium channel antagonists, theophylline, proton
pump inhibitors, or histamine-2-receptor antagonists) were
withheld at least 5 days prior to manometry and pH moni-
toring. When the examination could not be realized in the
ambulatory setting, it was done in the hospital setting.
Esophageal manometry
After a minimum 8-hour fasting period and the use of
topical anesthesia, the manometric probe catheter was
introduced through the patient’s nose and positioned
within the stomach. The 8 lumens of the polyvinyl catheter
(Arndorfer model Z432) were infused with double-distilled
water by a continuous infusion pump (Arndorfer Medical
Specialities, Grendale, WI, USA) with a constant flow
obtained by infusion of nitrogen (nitrogen pressure of
12,000 KPA). With the 4 distal side holes of the manometric
tube spaced radially, the pressure at the lower esophageal
sphincter was recorded. For the peristalsis evaluation, the
esophageal manometric tracing was recorded with a slow
pull-through of the manometric tube, centimeter by
centimeter.27
Esophageal pH monitoring
Aftermanometric evaluation, esophageal pHmonitoringwas
done using a single catheter containing 2 antimony pH
electrodes (Synetics Medical, Sweden), introduced through
the nose and positioned with the distal electrode 5 cm above
the lower esophageal sphincter (manometrically defined)
and with the second electrode 20 cm above the lower
esophageal sphincter. The catheter was externally con-
nected to a data storage device (Digitrapper Mark III Gold,
Synetics Medical, Sweden). After 24 hours, the catheter was
removed, and the data transferred from the digitrapper to
the computer. The analysis of data was done using Esopha-
gram pH computer software (Synetics Medical, Sweden).
Abnormal distal and proximal gastroesophageal reflux
were considered if the pH dropped to less than 4.0, for
a period greater than that determined by previously pub-
lished data, calculated for both the upright and recumbent
periods.28
Data analysis
Statistical analysis was performed, using SPSS (Statistical
Package for Social Sciences) for Windows version 11.0.
Because the data were not normally distributed, statistical
comparison of mean pulmonary function data (values as
percentage predicted) was done using the ManneWhitney
test. For group comparisons involving binary data and todetermine the significance of the differences in preva-
lence, we used either the chi-square test or Fisher’s exact
test. p Values of less than 0.05 were considered significant.
Results
As shown in Table 1, there was a great predominance of
women (49 women and 1 man), but none was pregnant. The
mean age was 43 years (range, 23e66), and the mean
duration of the disease was 8 years (range, 1e23). Eight
subjects (16%) smoked cigarettes, but only one was still
smoking at the time of entry into the study. Thirty-seven
(74%) patients had typical reflux symptoms, such as heart-
burn or regurgitation, 30 (60%) complained of shortness of
breath, and 19 (38%) had a dry cough.
Pulmonary involvement on function tests
All 50 patients had lung function assessed. Total lung
capacity and DLCO were not performed in 2 and 1 patients,
respectively, due to lack of cooperation during the exami-
nation. The mean pulmonary values for the group are given
in Table 2.
Pulmonary involvement in high-resolution
computed tomography
Fifty patients underwent computed tomography of the
lungs; 39 patients (78%) had signs of interstitial lung disease
on tomography: ground glass opacities (nZ 36/50; 72%),
interface sign (nZ 22/50; 44%), subpleural linear opacities
(nZ 24/50; 48%), traction bronchiectasis (nZ 12/50; 24%),
honeycombing (nZ 12/50; 24%), air trapping (nZ 6/50;
12%) and consolidation (nZ 2/50; 4%). Interstitial lung
disease abnormalities were observed predominantly in the
lower, peripheral, and posterior lung areas. They are
described in Table 3.
Esophageal manometric involvement
Thirty-six patients underwent esophageal manometry.
According to esophageal impairment, patients were grou-
ped as follows: normal (nZ 6/36; 16.7%); moderate
dysfunction, which means patients with uncoordinated
peristalsis or lower pressure wave amplitudes or distal
Table 2 Pulmonary function data.
Variable n Mean
FVC% 50 82 (43e117)
TLC% 49 87 (54e126)
FEV1% 50 88 (48e115)
FEV1/FVC 50 86 (68e109)
DLCO% 48 87 (40e119)
Values expressed as % predict. FVCZ forced vital capacity;
TLCZ total lung capacity; FEV1Z forced expiratory volume in
1 second; FEV1/FVCZ forced expiratory volume in 1 second as
% of vital capacity; DLCOZ carbon monoxide lung diffusion.
Values in parentheses are ranges.
Table 4 Interstitial lung disease findings on HRCT in
patients with aperistalsismoderate impairment or normal
function in manometry.
HRCT finding Aperistalsis
(nZ 23)
Moderate
impairment
or normal function
(nZ 13)
P
Ground glass
opacities
22 (95%) 4 (30%) <0.0001
Interface sign 15 (65%) 2 (15%) 0.006
Linear opacities 14 (60%) 4(30%) 0.04
Traction
bronchiectasis
8 (34%) 1 (7.6%) 0.1
Honeycombing 7 (30%) 0 (0%) 0.03
HRCTZ high-resolution computed tomography of the lungs;
ILDZ Interstitial lung disease. P values were determined by chi
square test or Fisher exact test.
Mixed Connective Tissue Disease 857aperistalsis (nZ 7/36; 19.4%); and severe dysfunction or
total aperistalsis of the esophageal body (nZ 23/36;
63.9%). No significant differences existed among the groups
with respect to mean age or MCTD duration.
Comparison of esophageal manometric
involvement and pulmonary parameters
A difference in the presence of shortness of breath was
noted among patients with aperistalsis, moderate impair-
ment, and normal function on manometry (73.9% vs. 71.4%
vs. 20%, respectively; pZ 0.03).
Patientswith severeesophageal dysfunction (aperistalsis)
were comparedwith the 2 other groups together (normal and
moderate dysfunction) and had lower DLCO (76.4% vs. 96.6%,
respectively; pZ 0.02), but without a difference in total
lung capacity (81% vs. 93%, respectively; pZ 0.08).
Findings of interstitial lung disease on computed
tomography, except for traction bronchiectasis (34% vs.
7,6%, respectively; pZ 0,1), were more prevalent in
patients with aperistalsis than in patients with moderate
impairment or normal function (ground glass opacities: 95%
vs. 30%, respectively, p< 0,0001; interface sign: 65% vs.
15%, respectively, pZ 0,006; linear opacities, 60% vs. 30%,
respectively, pZ 0,04; honeycombing: 30% vs. 0%,
pZ 0,03), as shown in Table 4.
Comparison of esophageal dilatation on high-
resolution computed tomography and pulmonary
parameters
Esophageal dilatation was present in 28 patients (56%), and
an example is shown in Fig. 1. Comparing the meanTable 3 Interstitial lung involvement in high-resolution
computed tomography.
Signs of interstitial
lung disease
39/50 (78%)
Ground glass opacities 36/50 (72%)
Subpleural linear opacities 24/50 (48%)
Interface sign 22/50 (44%)
Traction bronchiectasis 12/50 (24%)
Honeycombing 12/50 (24%)
Air trapping 6/50 (12%)
Consolidation 2/50 (4%)percentage values of pulmonary function data between
patients with and without esophageal dilatation, significant
differences existed for total lung capacity (79 vs. 92;
pZ 0.009) and for DLCO (72 vs. 100; pZ 0.004), as shown
in Fig. 2. The prevalence of interstitial lung disease on
computed tomography was significantly higher in patients
with esophageal dilatation (92% vs. 45%; pZ 0.001).
Computed tomography findings in patients with and without
esophageal dilatation are shown in Table 5.
Gastroesophageal acid reflux
Thirty-six patients were evaluated with 24-hour esophageal
pH measurements, and they were grouped according to the
presence or absence of abnormal acid reflux. Eighteen
patients (50%) had distal abnormal acid reflux, and 6 (16%)
had acid reflux at a proximal level. The presence of severe
esophageal dysfunction (aperistalsis) on manometry was
not statistically significantly related to proximal (pZ 0.38)
or distal reflux (pZ 0.16).
Comparison of gastroesophageal acid reflux
and pulmonary parameters
When we compared pulmonary functional parameters in
patients with normal and abnormal proximal reflux, no
statistically significant differences were noted between the
means of total lung capacity (84.2 vs. 89.8, respectively;
pZ 0.35) or DLCO (82.7 vs. 89.1, respectively; pZ 0.91). In
the groups with normal and abnormal distal reflux, no
statistically significant differences were noted either
between the means of total lung capacity (87.2 vs. 83.5,
respectively; pZ 0.67) or DLCO (81.3 vs. 86.1, respec-
tively; pZ 0.61).
No statistically significant differences existed in findings
of interstitial lung disease on computed tomography
between patients with normal and abnormal proximal
reflux: ground glass opacities (21/30, 70% vs. 5/6, 83%,
respectively; pZ 0.65), interface sign (16/30, 53% vs. 1/6,
16%, respectively; pZ 0.18), linear opacities (15/30, 50%
vs. 2/6, 33%, respectively; pZ 0.66), traction bronchiec-
tasis (8/30, 26% vs. 1/6, 16%, respectively; pZ 1.0), and
Figure 1 HRCT showing esophageal dilatation in a patient
with DMTC (the esophagus has an air-fluid level).
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pZ 0.57).
Interstitial lung disease findings on computed tomog-
raphy were more frequent in the group of patients with
abnormal distal reflux than in patients with normal distal
pH monitoring, but without statistical significance. The
findings for these groups were, respectively, ground glass
opacities (15/18, 83% vs. 11/18, 61%; pZ 0.26), interface
sign (10/18, 55% vs. 7/18, 38%; pZ 0.5), linear opacities
(11/18, 61% vs. 6/18, 33%; pZ 0.18), traction bronchiec-
tasis (7/18, 38% vs. 2/18, 11%; pZ 0.12), and honey-
combing (6/18, 33% vs. 1/18, 5%; pZ 0.08).
Discussion
Our findings are significant because interstitial lung
disease, gastroesophageal reflux, and esophageal motor
impairment are very common and frequently coexist in
patients with MCTD. The main signs of interstitial lung
disease (ILD) in our study were ground glass opacities (72%),
with peripheral and lower lung predominances, consistent
with previous studies.7,9 Statistically significant correla-
tions were noted between severe esophageal motor
dysfunction and evidence of interstitial lung disease on
DLCO and computed tomography. Moreover, we have shownFigure 2 Mean values and confidence intervals of DLCO (% pre
without esophageal dilatation.that the prevalence of ILD on computed tomography was
more common in patients with esophageal dilatation on
tomography scans. However, the presence of abnormal
proximal or distal gastroesophageal acid reflux was not
significantly associated with evidence of ILD, and as
a result, we were not able to attribute the correlation
between aperistalsis and lung injury to acid reflux.
Gastroesophageal reflux has been associated with
several airway manifestations, including chronic cough,
asthma, chronic bronchitis, and bronchiectasis.29e32 Two
mechanisms have been postulated to explain the relation-
ship between acid esophageal reflux and lung disease:
bronchoconstriction induced by esophageal acid and
microaspiration causing pulmonary damage.33 More
recently, gastroesophageal reflux has been postulated as
a possible causal factor in patients with ILD.13,17e19
Patients with systemic sclerosis, MCTD, and polymyositis
have a high prevalence of esophageal and pulmonary
involvements, but proving a causal relationship is difficult.
Few investigators have explored the relationship between
esophageal involvement and interstitial lung disease in
systemic sclerosis, with conflicting results.11,12 Marie et al.11
found a correlation between the severity of esophageal
motor disturbances on manometry and evidence of inter-
stitial lung disease in these patients and concluded that acid
reflux may contribute to this lung injury. However, Trosh-
insky et al.12 have failed to show any correlation between
abnormal gastroesophageal acid reflux and evidence of
interstitial lung disease on pulmonary function in these
patients. Caleiro et al.21 have shown a correlation between
pulmonary abnormalities and esophageal dysfunction on the
scintigraphic evaluation and in the hystopathological
examination of the esophagus, but they could not establish
a causeeeffect between them in MCTD patients.
The phenomenon of independent food and acid reflux
has been evaluated by several groups. The results obtained
from esophageal pH monitoring and those from gamma
scintigraphic detection of reflux show that there is a poor
correlation between the reflux of food and acid detected by
the 2 techniques, with significantly more reflux episodes
recorded by scintigraphy.34e37
Although in our series we did not evaluate the presence
of food reflux, it is a reasonable mechanism to explain thed) and TLC (% pred). Comparison between patients with and
Table 5 Interstitial lung disease findings on HRCT in
patients with and without esophageal dilation.
HRCT
finding
Normal
esophagus
(nZ 22)
Dilated
esophagus
(nZ 28)
P
ILD prevalence 10 (45%) 26 (92%) <0.001
Ground glass
opacities
10 (45%) 26 (92%) <0.001
Interface sign 6 (27%) 16 (57%) <0.05
Linear opacities 7 (31%) 17 (60%) 0.05
Traction
bronchiectasis
2 (9%) 10 (35%) <0.05
Honeycombing 3 (13%) 9 (32%) 0.18
HRCTZ high-resolution computed tomography of the lungs;
ILDZ Interstitial lung disease. P values were determined by chi
square test or Fisher exact test.
Mixed Connective Tissue Disease 859correlation between aperistalsis and lung damage in the
absence of acid reflux. A previous study described a pattern
of fibrosis, named centrilobular fibrosis, with a bronchiolo-
centric distribution and presence of intraluminal foreign
bodies, suggesting that chronic aspiration could lead to
pulmonary fibrosis.38
By far from entirely resolving the controversy about the
relation between esophageal dysfunction and interstitial
lung involvement, our series underscores a correlation
between the finding of aperistalsis on manometry
and evidence for interstitial lung disease on DLCO and
computed tomography. The correlation between DLCO and
interstitial lung disease, but not between total lung
capacity and interstitial lung disease, is probably due to the
fact that reduced DLCO is the most sensitive test for pre-
dicting interstitial lung disease in these patients, preceding
the reduction in total lung capacity.9
Our findings suggest that interstitial lung disease may be
associated with food reflux in patients with mixed
connective tissue disease, because it was more common in
those with esophageal dilatation on computed tomography
scan and with severe esophageal dysfunction on manom-
etry. As a result, it strengthens the recommendation to
screen regularly patients with MCTD, especially those with
esophageal motor impairment, for pulmonary involvement.
However, we were not able to attribute the pulmonary
damage to acid reflux.
Although some authors have previously suggested that
aggressive treatment of gastroesophageal reflux can
decrease deterioration of pulmonary function in patients
with interstitial lung disease, our results stress the need for
further prospective and randomized trials to prove the
beneficial effect of prokinetic therapy and proton pump
inhibitors on interstitial lung disease.11,39
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